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Chapter 2 described the evolution of a generic therapeutic principle on which the 
clinical fields of renal and other kinds of whole organ transplantation are based. 
In kidney recipients who were treated with azathioprine and prednisone in 1962 
and 1963, a characteristic cycle was recognized in which rejection in the first post-
operative days or weeks could be reversed with increased doses of steroids. 1 
Following this critical period, in successful instances it was frequently possible to re-
duce (Fig. 9-1) or rarely, as it turned out much later. even to stop immunosuppres-
sion. 
The reproducibility of these events after renal and subsequently other kinds of 
organ transplantation led to the therapeutic practice that can be observed in every 
transplantation clinic today. It calls for daily baseline treatment with a maintenance 
drug (or drugs) plus trial and error intervention with the highly dose-maneuverable 
adrenocortical steroids to whatever level is required to maintain stable graft func-
tion. This can be accomplished without (double-drug therapy) or with the adjuvant 
use of antilymphoid or other agents in triple or quadruple drug cocktails. 
Throughout the years. this framework of treatment has accommodated increasingly 
potent new agentsO~gK The most commonly used drugs are summarized in Table 9-J. 
A great appeal of this empirical therapeutic approach was its simplicity and the 
consequent ease with which it could be taught or modified. Anyone with reasonable 
clinical judgment could become an expert after experience with a few patients. Of 
equal practical importance. the algorithmic steps were not drug specific except for 
the use of prednisone as a common constituent. Although the other indiVidual drugs 
219 
I 
I 
Ii 
I 
! 
I! 
220 • RENAL TRANSPlANTATION 
150 
10 
Ccr 5 
(mil minI 0 
150 
BUN 100 
(mgm '1(,1 50 
0 
wec 
(mm 3 ) 30,00 
20,00 
10,000 
o 
600 
400 
Azathioprine 
(mgm/dayl 20 
Prednisone 
(mgm/day) 
x 
.... 
OUT -PA TIENT 
PT. J.R. 
23 YO 0' 
OMMi---~ ____ ~ ____ ~ __________________ ~~ ______ ~ __________ __ 
--Apfll----May --- -June--_ --JUly--- Aug Sept Oct Nov Dec Jan Feb Mar Apr 
1963-- '964 
Figure 9-1 . The characteristiC cycle of immunologic confrontation and recovery after organ transplantation (in this case 
a kidney) that has dictated the use of immunosuppressive drugs for the last 30 years. After a period of good postop-
erative renal function, relection 2 1/2 weeks after transplantation (Tx) was correlated with a fall in creatinine clearance 
(Ccr), a rISe in blood urea nitrogen (BUN), and an Increase in circulating white blood cells (WBC). The adverse findings 
were reversed With prednisone, which was later discontinued along with a reduction of maintenance azathioprine. The 
kidney allograft in this 23-year-old man functioned continuously from April 1963 until 1990. when the patient died of 
myocardial infarction. IFrom Starzl TE, et 01: Donor cell chimerism permitted by ImmunosuppresSIve drugs: a new VIew of organ transplanta-
tIOn. Immunol Today 14:326-332. /993.1 
in these cocktails were increasingly characterized in terms of their cellular or mole-
cular site of disruption of the alloactivated T-cell response. IO· 11 the cycle of post-
transplant recovery was always much the same. differing only in the ease and relia-
bility with which it could be negotiated. 
The events of convalescence suggested all along that the drugs or other treat-
ment modalities were affecting a common pathway by facilitating some kind of nat-
ural immunologic change in the host. the graft. or both. I:!. 1:1 This concept was con-
sistent with a number of early experimental observations in our laboratory. In 
1962-1964. drug-free clogs that had survived with kidney or liver allografts for pro-
longed periods or permanently after a 4-month course of azathioprine had inexplic-
able waxing and self-resolving rejectionsKf~K t:l In discussing the alterecl immunologic 
" 
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TABLE 9-1 ... DRUG COCKTAILS WITH EMPHASIS ON DOSE MANEUVERABILITY OF 
ADRENAL CORTICAL STEROIDSa 
Year Described 
Agents and Reported Place Deficiencies 
Azathioprine. steroids 1963 Denver Suboptimal 
Antilymphocyte globulin 1966 Denver Suboptimal 
(ALG) as adjunctb 
Cyclophosphamide substitute 1970 Denver No advantage except for 
for azathioprine patients with azathioprine 
toxicity 
Total lymphOid irradiation 1979 Palo Alto. Dangerous. extensive 
Minneapolis preparation. not quickly 
reversible 
Cyclosporine alone or with 1978-1979 Cambridge. Suboptimal 
cytotoxic drugs' England 
Cyclosporine. steroidsd 1980 Denver Nephrotoxicity; rejection not 
always controlled 
FK 506, steroidsd 1989 Pittsburgh Nephrotoxicity; rejection not 
always controlled 
Reference 
I 
2 
4.5 
6 
7 
8 
'Until 1966. these cocktails were developed for kidney transplantation and applied to liver transplantation. From 1966 onward. the liver 
Increasingly became a dominant test organ, 
bOriginal ALGs were polyclonal: monoclonal ALG (OKTJ) introduced in 1981.9 
'Steroids were given to some of these patients. but the therapeutiC objective was avoidance of steroids, 
dCompatlble with azathioprine or antilymphold drugs as third or third and fourth agents, 
environment following transplantation in 1964. it was suggested. as it turned out cor-
rectly, that: 
Prevention of rejection is not entirely dependent upon immunosuppressive agents: a 
key factor involves a dynamic biologic process in which the immunologic relationship 
between the host and graft changes rapidly, .. , Through pharmacologic Of other 
means it may become possible to augment the biologic changes .... An example of 
this last possibility is the current research in many laboratories which is directed to-
ward achieving enhancement by inoculating the recipient with [donorJ spleen. liver 
or peripheral white celis, Ie 
This strategy. in which bone marrow was the ideal source of augmenting donor 
antigen. was to become the dominant theme for more than two decades in Monaco's 
research laboratories II-II; and elsewhere. However. it was assumed that survival of 
these cells was limited to a few weeks. 
It was soon learned that the postulated "dynamic hiologic process" sometimes 
occurred without immunosuppression. as was demonstrated after liver transplanta-
I 
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tion in pigs by Garnier et al,17 Peacock and Terblanche,18 Caine et al 19 and US,20 
Porter,21 who had access to tissues from the different research groups, summarized 
the histopathologic proof that these "non-rejecting" pig recipients were actually go-
ing through subclinical rejection and spontaneous remission. Corry et al22 and 
Russell et af~P showed the same thing after heart and kidney transplantation between 
certain strains of mouse recipients. 
Hypotheses to explain graft acceptance under immunosuppression or some-
times without it invoked multiple mechanisms, including graft adaptation, clonal 
deletion, antibody enhancement, defective macrophage function, and the develop-
ment of suppressor or veto cells. 12.13.24-29 However, we suggested that the proposed 
elements of these "concatenation" hypotheses are epiphenomena of the key events 
of cell migration, repopulation, and systemic chimerism30-36 on which the ultimate 
acceptance of kidney and other whole organ grafts depends. In this context, the im-
munosuppressive drugs used clinically are facilitators that allow the bidirectional 
host-graft leukocyte migration that leads in successful cases to mixed chimerism in 
the recipient as well as the transplanted organ (Fig. 9-2). In addition to explaining 
how allografts are accepted, this concept can be used to improve future therapeutic 
strategies. 
t 
G V H 
Mutual Natural 
Immunosuppression 
t 
HVG (Rejection) 
Figure 9-2. The mutual engagement of migratory Immunocytes from the graft and the recIpient after organ tr'nsplan-
Dtlon under potent pharmacologIC Immunosuppression The stars represent the migrated cells. UbiqUitous chimerISm 
was Inferred from the more extenSive studies In reCIpients of liver, kidneys, and other organs, GVH, graft versus host; 
HVG, host versus graft. 
~ CHIMERISM IN KIDNEY RECIPIENTS 
Historical Neglected (lues 
Graft Adaptation 
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A much discussed hypothesis in the early 1960s was that kidney grafts underwent a 
diminution in allogenicity after transplantation. Such a change had been noted a 
decade before by Woodruff in thyroid tissue during a period of privileged sanctuary 
in the anterior chamber of the guinea pig eye. When Woodruff's "conditioned" en-
docrine grafts were retransplanted to a subcutaneous location in the same recipient. 
they were not rejected as normally would have occurred.J7.38 The inability to explain 
logically how genetically proscribed transplant antigens could change their charac-
ter caused this "graft adaptation" concept to lose favor. Later, it was shown in skin 
graft experiments that the antigenicity change was due to depletion of the donor in-
terstitialleukocytes in the graft and their replacement with a recipient population.39 
The kidney transplants became genetic composites.33.40 
Adoptive Transfer 
The results of exhaustive skin test studies (tuberculin. histoplasmin, blastomycin. 
coccidioidin. mumps, Candida. and Trichophyton) in our early Colorado kidney re-
cipients and their donors provided an additionallead4l but one that was not consid-
ered plausible at the time. Seventy-seven percent of the skin reactions that were pos-
itive preoperatively in the donors but not in the patients crossed over to the 
previously negative recipients in successful cases. along with the transplanted kid-
ney (Fig. 9-3). Wilson and Kirkpatrick. the immunology fellows who performed these 
studies under the supervision of David Talmage, speculated that the secondary ac-
quisition of the positive skin tests was "caused by adoptive transfer of donor cellu-
lar immunity by leukocytes in the renal graft vasculature and hilar lymphoid tis-
sue.···11 
The implication that cells from the graft had migrated into recipient tissues was 
considered untenable nearly 3() years ago because the kidney then was thought to be 
a leukocyte-poor organ. Instead. the transfer factor of Lawrence l :! was suggested as 
an alternative explanation. Ironically. several of these original patients were actually 
found to have chimerism nearly three decades later.;:; 
Modern Technology of Chimerism Detection 
The search in April-.July 1 ~F9:D! for chimeric cells in transplanted kidney and other 
kinds of whole organs and in recipients WilS made feasible by the distinctive features 
of two chromosomes.;Il-Ic, In female recipients of organs from male donors. the pres-
<'lICe of cells with the Y chromosome in recipient tissues (or blood) was cllnsidered 
llnequivocal evidence of systemic chimerism ... 'dternatively. probes were llsed that 
detected human leukocyte ilnti~en (HL\) alleles of chromosome 6. For study of ei-
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Figure 9-3. Transfer of positive skin test results from kidney donors to recipients at the University of Colorado from 
1962 to 196441 Although inexplicable at the time, these observations reflected adoptive transfer after cell migration, 
repopulation, and chimerism. (From Starzl T£. er 01: Cell m;gratJon and ch,merrsm after whole organ transplantation: the baSiS of graft ac-
ceptance. Hepatology 17: 1127-1152, 1993.) 
ther the Y chromosome or chromosome 6, one or the other of two techniques, and 
usually both, were used. Cytostaining allows the location and morphologic charac-
terization of phenotypically distinct donor and recipient cells. The polymerase chain 
reaction (PCR) is used to differentiate donor from recipient DNA. 
Cytostoining 
Staining for the Y probe was performed with a fluorescence method after in situ 
hybridization. Immunostaining for the HLA markers was with monoclonal anti-
bodies to class I and class II antigen phenotypes present in the donor but not the 
recipient. Staining with irrelevant anti-HLA antibodies and omission of the pri-
mary antibody provided negative controls (See Color Insert. Part C). Tissues with 
known HLA antigens along with the allograft biopsy and skin sections of the re-
Cipient stained with matching anti-HLA monoclonal antibodies were used as posi-
tive specificity controls. 
Polymerase Chain Reaction 
In the PCR search for the Y chromosome. oligonucleotides specific for the satellite 
region of the Y chromosome centromere Y-A I.l and for the sex-determining region of 
the Y chromosome II were used as primers to determine the presence of male DNA 
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in the female recipient tissues.31 After Southern blotting, the amplified material was 
hybridized to radioactively labeled Y-specific probes. PCR tests for donor- and 
recipient-specific HLA alleles of chromosome 6 were performed according to the 
reference protocol of the XIth International Histocompatibility Workshop.45 With this 
protocol, preliminary generic amplification of the ORB gene is performed followed by 
allele-specific amplification and testing. 
Direct Evidence of Chimerism 
One of the five kidney recipients who were studied 27-29 years after transplanta-
tion had stopped immunosuppression 12 years earlier. The others were still taking 
azathioprine with or without prednisone. These five patients were selected for the 
chimerism study33 in preference to other surviving kidney recipients from the 
1963 era for three reasons. First, four of the five donors still were alive, allowing 
HLA retyping and use of their lymphocytes for studies of immunologic compe-
tence of the recipient. Second, known HLA incompatibilities between these four 
donors (three parents, one aunt) and their recipients allowed immunocytochemi-
cal and PCR differentiation of donor from reCipient cells in the biopsy tissues, as 
described in the preceding section. In the fifth case, in which the donor in a father-
to-daughter transplantation had died, chimerism in tissues could be determined 
by sex typing. 
In each of four kidney recipients whose donor was alive, leukocytes with the ap-
pearance of dendritic cells that had migrated from the renal allografts were found in 
recipient skin and lymph node biopsies. Although they were few in number, these 
HLA mismatched donor cells were unmistakable with the immunostaining tech-
niques (See Color Insert, Part B). Chimerism was confirmed with PCR in the recipient 
tissues of all four of these patients and in the blood of two of them (Fig. 9-4). In the 
fifth patient, the woman who had been given her now-deceased father's kidney 29 
years previously, cells with the Y chromosome were found in her skin with fluores-
cent in situ hybridization studies and confirmed with PCR. 
In all five cases, biopsies of the kidney showed that the vascular endothelial 
cells remained donor. The tubular epithelial cells, which did not express HLA anti-
gens well, were proved to be donor with sex karyotyping. In contrast. the leuko-
cytes departing the allograft had been replaced by similar cells from the recipient 
(See Color Insert. Part A). Thus in addition to showing systemic chimerism. it was 
established that the kidney grafts were chimeras-composed of cells with two dif-
ferent genomes:n (Fig. 9-2). 
Two of the four recipients of kidneys from the still-living donors had no clonor-
specific reactivity by mixed lymphocyte reaction (MLR), whereas the other two hac! 
greatly reduced antidonor reactivity. With cell-mediated Iymphocytotoxicity testing, 
all four were nonresponsive to donor lymphocytes. Three of the four patients were 
otherwise fully immunocompetent with responsiveness to third-party lymphocytes 
and mitogens .. u 
\ 
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DB RB RL RS c 
Figure 9-4. LD 90:PCR demonstration with Southern blot technique of chimerism in blood (RB), lymph node (RL), and 
skin (RS) of the recipient as detected with DR7 (donor) specific oligonucleotide probes. DB. donor blood DNA diluted 
100 times to avoid overwhelming the other bands. (From Starzl TEo ~l 01: Chim~nsm and donor specific nonr~activity 27 to 29 years 
aft~r kidney allotransplantation. T ranspl.ntation 55: 12 72-12 77. 1993.) 
A LIVER AND OTHER ORGANS 
Graft Chimerism 
Another underappreciated clue to cell migration was the demonstration in 1969 that 
the Kupffer cells and other interstitial monocytes and macrophages of a transplanted 
human liver were replaced within 100 days by cells of reCipient phenotype.46 A com-
pOSite (chimeric) structure was shown in 1991 also to be a feature of long-surviving 
transplanted intestine in rats 47 and humans. 48 The suspicion that this process must 
be generic in all successfully engrafted organs soon was confirmed.35 
Systemic Chimerism 
Like the kidney recipients, most of a cohort of 25 liver recipients studied for chime-
rism were clinically well and fully immunocompetent according to conventional in 
vitro testing 2-22 years after transplantation under azathioprine- or cyclosporine-
based immunosuppression.35 Donor cell chimerism was found with cytochemical or 
PCR techniques in all 25 patients in locations that included skin, lymph nodes, heart, 
lungs, spleen, intestine, kidneys. bone marrow, and thymus. Chimeric cells were 
present in larger numbers at any given site than in the contemporaneously studied 
long-surviving kidney recipients. 
A CELL TRAFFIC AND SITES OF DONOR-RECIPIENT IMMUNOLOGIC INTERACTIONS 
The early events leading to the chimeric state have been studied in rats:Hi and mice. 1'1 
including the pathways of passenger leukocyte dissemination. Within minutes or 
hours, these cells leave the graft and home to the central lymphoid organs (spleen, 
lymph nodes. thymus, and probably bone marrow), and are destroyed by rejection 
in most animals except mice. However. with temporary immunosuppression in rats 
(2 weeks of daily FK 5(6), these mononuclear cells pause tor about 2 weeks in the 
DK~K 
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lymphoid organs but then break out and move secondarily to all recipient tissues36 
(Fig. 9-5). Rat liver recipients treated this way (LEW to ACl) survive indefinitely with-
out further treatment and retain their graft and systemic chimerism. 
Interestingly, cell migration and chimerism, with permanent survival of the en-
grafted livers, occur without any immunosuppression in some rat strain combina-
tions (Brown Norway to Lewis for example), and occur without treatment in vir-
tuallyall mouse strain combinations. The liver recipients in either species can accept 
skin, kidney, or a heart from the original donor strain but no other (donor-specific 
nonreactivity).36.49 This kind of evidence has indicated that the heavy endowment of 
the liver with potentially migratory white cells is the basis for the well-known but 
previously inexplicable phenomenon of "hepatic tolerogenicity." This term has been 
used to define the ability of the liver to induce its own acceptance or that of com-
panion organs more readily than other kinds of allografts and in some experimental 
models without immunosuppression. 13.17-20.47.50-53 
By the end of 1992, it was appreciated that all whole organs undergo the same 
process of potential tolerance induction as the kidney and liver,34.35 the dynamics 
being particularly easy to study with the leukocyte-rich intestine.54.55 The same 
Figure 9-5. The dissemination of passenger leukocytes from the graft (rat liver In these experiments) to the central 
lymphoid organs and then ubiqUitously after a brief pause. The events are Similar to those after successful bone mar-
row transplantatlon.)6 
I I 
228 .A. RENAL TRANSPlANTATION 
kind of traffic in the context of alloactivation and rejection rather than tolerization 
had been well worked out earlier with the so-called lymphoid-poor organs, includ-
ing the kidney. Studies with untreated animals have shown that the alloreaction 
starts in two general sites, peripherally in the graft and centrally in the recipient 
lymphoid tissues. 
In a remarkably complete study in 1981 of untreated rat kidney recipients, 
Nemlander et al56 demonstrated the same kind of leukocyte migration as we noted 
with rat liver allografts 12 years later.36 If Nemlander et al had given one or two doses 
of cyclosporine to their recipient animals (an "easy" strain combination) and had fol-
lowed them further, they almost certainly would have uncovered the events of cell 
migration and repopulation that awaited another 12 years for exposure with the 
liver.36 Larsen et al57 found that donor dendritic cells from heterotopic cardiac allo-
grafts are released into the circulation, where they eventually home into the T-cell ar-
eas of the recipient spleen. In the spleen, the donor cells initiate proliferation of re-
cipient cells and vice versa.56-60 This reaction might be considered to be an in vivo 
MLR and epitomizes central allosensitization. 
Allosensitization (and tolerization) presumably also occur within the graft. 
Forbes et al59 were the first to show that clustering of recipient lymphocytes occurs 
around donor dendritic cells in the interstitium of cardiac grafts within a few days af-
ter transplantation. The recipient lymphoid cells undergo blastogenesis and prolif-
erate within these clusters. We have described analogous events in the rejection of 
rat livers.58 
In human recipients of kidney grafts under cyc!osporine-prednisone immuno-
suppression, Hayry and Willebrand6 1.62 noted what appeared to be a bidirectional 
MLR in needle aspiration biopsies. When studied with the Staphylococcus aurem as-
say and alloantibodies to nonshared donor and recipient allelic specificities, most of 
the collected blast cells in some cases were derived from the donor or else the re-
sponse was split, "resembling a bidirectional mixed lymphocyte reaction in vitro. "til 
... FUNOIONAl CONSEQUENCES OF MICROCHIMERISM 
Cause and Effect? 
Questions have continued to be raised whether the low-level chimerism found in our 
long-surviving patients and experimental animals:!o-:ls was an irrelevant histopatho-
logic curiosity or a condition with immunologic significance. This has been surpris-
ing in view of Russell's elegant formal proof of the association of chimerism with ac-
quired tolerance as well as runt disease,!i:1 The skepticism arose because the 
chimeric donor cells were so sparse in recipient tissues of the patients and the ani-
mals of our studies. The term fTllcroc/Zimensm (as opposed to macrochimensm) to de-
scribe a small proportion of chimeric cells in recipient blood was introduced by 
Liegeois et al,i.! in 1974 in a report of experiments with the mouse model used earlier 
by Monaco et al.'" Far from being insignificant. there is much evidence that the cu-
mulative effect of these microchimeric cells is substantial. especially after liver trans-
plantation. in which they are most easilv demonstrated. 
- . 
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Metabolic Implications 
The small population of chimeric cells has been shown to affect total body metabo-
lism in patients treated with liver transplantation for the enzyme deficiencies of type 
4 glycogen storage disease and Gaucher's disease in which the consequences of the 
missing enzymes are widespread storage of amylopectin and B glucocerebroside, re-
spectively.32 These disorders were thought to be treatable only by bone marrow 
transplantation because the enzyme deficiency is of all cells. Two to 8 years after 
liver replacement, however, there was a dramatic resorption of both kinds of storage 
material from host tissues. As an explanation for the metabolic amelioration, 
chimeric donor cells were found ubiquitously in recipient tissues. including heart. 
lymph nodes, bone marrow, intestine. and skin. There apparently had been a cocul-
ture effect of a small number of chimeric donor cells on the contiguous overwhelm-
ing numbers of enzyme-deficient recipient cells.32 
If, as we have conciuded,30-36 chimerism differing only in degree with different 
kinds of organ allografts is an integral feature of all successful engraftments. any such 
procedure can result in such a gain of systemic metabolic function, as suggested 
for different reasons by Groth et al66 in 1979. Although the chimerism in our long-
surviving kidney recipients was only one fifth or less of that in the liver recipients. 
this may have been enough to explain an enigmatic observation made in 1972 by 
Desnick et al.°7 After successful renal allotransplantation, this group at the University 
of Minnesota described recovery of function in the patient's diseased kidneys. which 
had been shut down by the glycosphingolipid accumulations of Fabry's storage dis-
ease. A reasonable hypothesis is that donor chimeric cells had settled there (Fig. 
9-6). 
The Immunologic Interface 
The foregoing metabolic observations raise important questions about potential 
analogous cell-to-cell effects of other molecules directly involved in immunologic 
processes. including those subserving tolerance induction. Much needs to be 
learned about how the chimeric donor cells. many of which resemble dendritic cells. 
are perpetuated for as long as three decades after transplantation. The dendritic and 
other leukocytes could be spawned by small numbers of pluripotent progenitor cells 
coming from the allograft interstitium. Dendritic cell precursors have been grown 
from mouse blood. bone marrow. or whole organs by means of granulocyte-
macrophage colony-stimulating factor (GM-CSF)-enriched mediaKD;D~ Alternatively. tis-
sue leukocytes in the organ may not have reached terminal differentiation as previ-
ously assumed. We have suggested that subsequent survival and renewal of these 
cells depends on chronic mutual stimulation of the donor and recipient cell popula-
tions:1u,; in a process of tolerization that has many of the cellular characteristics as-
sociated with immunitv."tl However. there has been IlO direct wav to test how this 
small population of donor dendritic and other cells can have all impact far exceed-
ing its numbers. 
I , 
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Figure 9~K Explanation for 1972 observation by Desnick et al67 of recovery of native kidneys after successful renal 
transplantation for Fabry disease. The migration of passenger leukocytes from the allograft to the host kidneys and else-
where is shown with black stars. 
Changed Host and Graft Interactions 
There are many indications that the coexisting immunocyte populations in success-
ful transplantations come to regard each other in a revised light. The eVidence on 
one hand is the fading of the threat of clinical rejection concomitant with develop-
ment of decreasing donor-specific reactivity in spite of lightened treatment and on 
the other the waning specter of graft versus host disease (GYHD). It is quite natural 
to expect that the threat of GYHD would decline at the same time as the threat of 
rejection. because both of the cell populations are receiving the same protective 
immunosuppression in an organ recipient. Appreciation of the intercellular relation-
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ship and the need not to alter it by ablating one side or other was the crucial con-
ceptual advance allowing the successful engraftment of leukocyte-rich organs such 
as the liver, intestine, both together, or all of the intra-abdominal organs (multivis-
ceral transplantation).70 Once it was proved that low-level mixed allogenic chimer-
ism invariably was found after successful whole organ transplantation, the reason 
seemed clear why GVHD was not common among recipients of liver, intestinal, or 
multivisceral transplants. The explanation was that mixed chimerism was being pro-
duced in the same way as in the classic GVHD-free mouse bone marrow mixed 
chimerism models of Slavin et al 71 and I1dstad and Sachs.72 
The Critical Dendritic Cell 
Generation of an immune response that leads under normal circumstances to graft 
destruction or GVHD requires effective antigen presentation and recognition in the 
initial phase followed by a second costimulatory signal and the response of T cells 
to the combined signal.73 Both of these signals are normally delivered to T cells by 
professional antigen-presenting cells (APC). Of these APCs, the dendritic ce1l74.75 (the 
most prominent chimeric cell according to morphologic criteria) is critical because 
it can modify the expression of cell interaction, major histocompatibility (MHC) lo-
cus, and adhesion molecules, all of which determine how antigen signals are heeded 
by T cells. 76 Thus the dendritic leukocyte is the prime candidate in this tolerogenic-
ity scenario, even though other lineages may also be essential for the successful out-
come of such an immunologic transaction. 
Impact on TIssue Matching 
In the directions of both host versus graft (rejection) and graft versus host cellular 
interactions resulting in "mutual natural immunosuppression" are envisioned as oc-
curring on a sliding scale with each further level of histoincompatibility (Fig. 9-7). 
With protection by modern-day immunosuppression. the alloreactions caused by the 
mutual cell engagement usually can be mitigated enough to allow the tolerogenic 
changes to occur and a rapprochement to be reached between the coexisting im-
munocytes. The anticipated histocompatibility influence on both rejection and the 
severity of GVHD are then expected to dwindle. We have postulated that this explains 
the poor correlation of HLA matching with outcome after cadaveric transplantation 
of whole organs. including the kidney.:1I1:11:IS 
A RELATION OF CELL MIGRATION TO TOLERANCE 
The inadequacy of thymic clonal Jeietion to explain acquired transplantation toler-
allce has been emphasized in recent reviewsK;~ Although a discussion of the meaning 
I 
1 j 
l 
1 
; I 
i " 
: : 
, , 
i 
232 6& RENAL TRANSPLANTATION 
Match 
Partial 
Mismatch .... iiiiiiiii. ____ ............ ___ ... iiiI .. 
Total 
M,smatcn 
Mutual 
Natural 
Immunosupresslon 
Figure 9-7. The donor-recipient leukocyte interaction IS a buffer against relection on one hand and graft versus host 
disease on the other. Veto and suppressor cells are postulated to be the result of the interaction shown at 
the cell population interface. R •• iatrogenic immunosuppression. (From Starzl TE, et 01: Donor cell chimerISm permitted by Immune>-
suppresSive drugs: a new view of organ transplantoaon. Immunol Today 14:326-332. 1993.) 
of tolerance is beyond our intention. it should be noted that all of the hypotheses to 
explain clonal "silencing," including peripheral clonal deletion and anergy, could 
mesh with the discovery of the enduring graft-host intimacy that is inherent with 
chimerism. 
The evidence of long-term Vitality and turnover of donor leukocytes i.n recipient 
tissues is particularly supportive of the opinions of Coutinho et alti~gKTe and Cohen. T~} 
who defined acquired tolerance as a high (not anergic) level of sustained immune ac-
tivity in networks. These networks presumably interact in a more complex way than 
the idiotype systems originally postulated by Jerne. slI Suppressor or veto cells or 
both could be epiphenomena of this kind of activity. 
Such a hypothesis would explain why cell migration and chimerism are a com-
mon mechanism of donor-specific nonreactivity no matter what the site of action of 
immunosuppressive drugs or in some experimental models without drugs. It has 
;~K 
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been proposed from observations in drug-free models of tolerance induction that T-
cell receptor occupancy leads to production of negative regulators of interleukin-2 
(lL-2) production (anergy proteins).73.81 According to this hypothesis, during the 
course of a normal T-cell response (to alloantigens) these negative regulators of IL-2 
production have an inconsequential effect because they are diluted out by vigorous 
cell replication driven by IL-2. However, these negative regulators would accumulate 
with consequent anergy if clonal expansion were prevented at any level (Fig. 9-8), for 
instance, by the absence of a costimulatory signal in drug-free models.73 
The same effect could be induced iatrogenically by pharmacologic interdiction 
of IL-2 gene transcription (cyclosporine and FK 506) or administration of a DNA syn-
dsea-~ 
Figure 9-8. Model of dendritic cell (APC)-T HI-<ell interaction shows the production Wlchln the nucleus 01 positive ( • ) 
.1nd negative (-) regulators (anergy proteins 1 of Interleukln-2 (ll-2) gene transcription. In thiS model. anergy relates 
only to the Il·2 gene. and other cytok,nes leg. Interferon-y) may be secreted. albeit at suboptimal levels. In the absence 
of persistent costlmulatory signals lor under the umbrella of Immunosuppressive drugs). cell diVision does not proceed. 
:1nd negative nuclear regulators accumulate. resulting In T-cell anergy. In addition to the action of Immunosuppressive 
.1gents. chroniC antigen stimulation IS also envIsioned as promoting anergy. In some Instances. tolerance can be broken . 
.1S by admlllistration of exogenous IL·2. HVG. host versus graft response (allograft rClectlon I: GVHD. graft versus host 
dlsease.IFrom Thomson AW. Stanl TE (("dE Immunosuppressive Drugs: London. Edward Arnold. 1993) 
I 
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thesis inhibitor (azathioprine, cyclophosphamide, and numerous others). The use of 
non-T-cell depleting monoclonal antibodies, such as those directed against the cell 
surface CD4 antigen or monoclonal antibodies against adhesion molecules, including 
ICAM-l and LFA-l,82 can also be envisioned. 
However it occurs, the reciprocal educational process of donor and recipient 
leukocytes and its perpetuation resembles in either the direction of rejection or 
GVHD (Fig. 9-8) the "infectious" transplantation tolerance that can be passed on to 
naive lymphocytes and be self sustaining in some circumstances.83 It is postulated 
that in fully successful transplantations, the mini-immune system of the graft is in-
corporated into the existing recipient immunologic network,34.36 compatible with the 
hypothesis of Coutinho.78 
... UNSTABLE MIXED CHIMERISM 
Cell migration conceptually reunites bone marrow transplantation with transplanta-
tion of whole organs. Far from involving different mechanisms for successful en-
graftment, we believe that these two seemingly disparate fields merely reflect con-
trasting treatment dogmas. For bone marrow transplantation, the conventional 
treatment strategy of recipient cytoablation eliminates mutual immunocyte engage-
ment and thus necessitates heavy reliance on HLA matching to prevent GVHD in the 
unbalanced system. The treatment for solid organ transplantation encourages, or at 
least allows, these consequences of mutual cell engagement, thereby liberating the 
patient from the restrictions of HLA matching and an overwhelming threat of GVHD. 
Failure of clinical organ transplantation implies the inability to achieve mixed al-
logeneic chimerism despite the best available immunosuppression-almost invari-
ably after kidney transplantation because of an imbalance that leads to rejection. 
However, because an incipient GVH reaction is a necessary condition for success 
(this is our fundamental premise), clinical GVHD is a possibility after every trans-
plantation. although the threat varies from organ to organ. We now know that about 
5% of all liver recipients experience a bout of clinical GVHD. which in the past usu-
ally was attributed to an allergic skin reaction.35 The incidence after kidney trans-
plantation is not known because it is not considered . 
... CLINICAL TRIALS OF BONE MARROW AUGMENTATION 
The concept developed in this chapter is that the content (and perhaps the specific 
lineages) of migratory cells that are particularly numerous in the liver confer poten-
tial immunologic advantages. These passenger leukocytes. which are of bone mar-
row origin, have been considered an immunologic liability for transplantationK~·1 
Under the appropriate conditions. however. they may be tolerogenic. as exemplified 
by the liver. A corollary. therefore. is that organs. such as the kidney and heart. with 
a smaller leukocvte component must have similar inherent. although less tolero-
genic. potential. The frequently advanced strategy of intravenous infusion of donor 
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bone marrow, donor blood (donor-specific transfusion), or other hematolymphoid 
cells at the same time or soon after transplantation of whole organs 14-16,64,65,71.72,85-87 
is merely an augmentation of the normal posttransplant cell migration, To mimic the 
natural process, these cells should be given perioperatively, not before or after the 
operation, as usually has been done with the so-called Monaco model. 
This strategy is currently under clinical evaluation, using bone marrow for the 
leukocyte augmentation. Since December 1992, over 70 patients with end-stage renal 
disease have received a simultaneous kidney-bone marrow allograft from the same 
cadaveric donor at our center. Additional renal transplant patients with diabetes 
(Type I) also have received a pancreas or pancreatic islets from their kidney-bone 
marrow donor. As a precaution, autologous bone marrow was harvested from the 
first 10 recipients immediately before kidney transplantation and cryopreserved for 
potential future use in case of GVHD.88 
The donor bone marrow was obtained from vertebral bodies at the end of multi-
organ procurement: 3-5 x 108 untreated bone marrow cells/kg were administered by 
means of intravenous infusion immediately after the kidney transplant. The patients 
with diabetes received the pancreas or pancreatic islets; the latter were infused intra-
portally. Intravenous bone marrow infusion was performed at the conclusion of the 
procedure. All patients were treated with FK 506 and steroids. Chimerism was assessed 
in the reCipients by flow cytometry, PCR, and immunostaining from peripheral blood 
lymphocytes. Immunologic monitoring was by MLR and cell-mediated Iympholysis. 
Detectable levels of donor cells were present in the peripheral blood lympho-
cytes of 90% of the recipients, Donor cells were also detected in two patients who un-
derwent lymph node biopsy 2 and 4 months after transplantation. One-year actuar-
ial patient and graft survival have been 100% and 98%, respectively. 
None of the recipients manifested GVHD. The only example we observed of such 
a potential bone marrow-related complication was in a patient who underwent 
550 cGy total lymphoid irradiation before a combined liver-bone marrow allograftK~e 
The unwise decision to produce an iatrogenic imbalance in the donor-reCipient in-
terface by means of total lymphoid irradiation was based on the dogma that "making 
space" would facilitate engraftment of the marrow. This concept has been eroded 
with direct experimentation.H<J.9o 
Further evaluation of passenger leukocyte augmentation (with bone marrow and 
other leukocyte sources) will be of particular interest for pancreatic islet transplan-
tation, This means of treating diabetes has conSistently failed because of the high 
rate of rejection.'11 If it is possible to increase islet allograft survival with minimum ul-
timate immunosuppression by concomitant donor bone marrow infusion. this will be 
an approach opposite to the numerous attempts to reduce islet immunogenicity by 
selective destruction of the bone marrow-derived antigen presenting cells that are 
normally contained in islet preparations,:J:! Then donor bone marrow would become 
a dose-maneuverable component of any organ or cellular transplantation for facilita-
tion of graft acceptance and induction of donor-specific nonreactivity. 
As discussed earlier, liver transplantation can be envisioned as a mini-bone mar-
row engraftment. Among a group of 44 human liver reCipients who had survived 
11-2:3 Years, six (14":,) had stopped all immunosuppression 1-11 years postopera-
. ,. 
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tively with subsequent, clinically stable, drug-free intervals of 5-13 years. Another.lS 
patients with shorter follow-up periods all were drug-free and in stable condition?,,·93 
The most extreme example of early successful drug discontinuation in a liver recipi-
ent was after 6 months, with a subsequent follow-up period of 3 years. A trial of drug 
weaning has been started in liver recipients with a rejection-free course exceeding 5 
years. Liver graft rejection (if it occurs) can be so effectively treated with FK 5068 that 
the benefits of discontinuation of drugs appear to outweigh the risks for selected pa-
tients. 
The liver experience in which the hepatic graft brings its own intrinsic quota of 
bone marrow-derived leukocytes should provide insight about what can be achieved 
with use of bone marrow augmentation for recipients of other organs or cells such as 
the kidney or pancreatic islets. Even if this strategy to obtain drug independence is 
successful, there is no way to know when a drug-free state has arrived. It seems clear 
that if the clinical experience with the tolerogenic livers is taken seriously, renal or 
heart transplantation with bone marrow augmentation also will require protracted 
immunosuppression before this treatment can be stopped altogether and then only 
with precautions. Such conclusions also have been reached by Barber et al86 using 
delayed supplementary bone marrow for cadaveric kidney transplantation as advo-
cated by Monaco. 
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Although this chapter was written in the spring and early summer of 1993, fur-
ther work in our laboratories and elsewhere have strengthened the hypothesis it 
contains. The work and progress of the last 3 years has been summarized in the fol-
lowing three recent reviews: 
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